Cargando…

CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake ((123/131)I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors

BACKGROUND: Neuroblastoma (NB) and pheochromocytoma/paraganglioma (PHEO/PGL) are neuroendocrine tumors. Imaging of these neoplasms is performed by scintigraphy after injection of radiolabeled meta-iodobenzylguanidine (mIBG), a norepinephrine analog taken up by tumoral cells through monoamine transpo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grand-Guillaume, Joana, Mansi, Rosalba, Gaonkar, Raghuvir H., Zanger, Sandra, Fani, Melpomeni, Eugster, Philippe J., Beck Popovic, Maja, Grouzmann, Eric, Abid, Karim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485979/ https://www.ncbi.nlm.nih.gov/pubmed/37679770 http://dx.doi.org/10.1186/s12967-023-04466-z

Ejemplares similares

Individualized (131)I-mIBG therapy in the management of refractory and relapsed neuroblastoma
por: George, Sally L., et al.
Publicado: (2016)

Cardiac (123)I-mIBG Imaging in Heart Failure
por: Verschure, Derk O., et al.
Publicado: (2022)

Nothing but NET: A review of norepinephrine transporter expression and efficacy of (131)I-mIBG therapy
por: Streby, Keri A, et al.
Publicado: (2015)

I-131 mIBG Scintigraphy Curie Versus SIOPEN Scoring: Prognostic Value in Stage 4 Neuroblastoma
por: Riaz, Saima, et al.
Publicado: (2018)

A European myocardial (123)I-mIBG cross-calibration phantom study
por: Verschure, Derk O., et al.
Publicado: (2017)

SPECT Imaging of SST2-Expressing Tumors with (99m)Tc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and Spacers
por: Gaonkar, Raghuvir Haridas, et al.
Publicado: (2021)

CUDC‐907 blocks multiple pro‐survival signals and abrogates microenvironment protection in CLL
por: Chen, Yixiang, et al.
Publicado: (2018)

Characterization of the HDAC/PI3K inhibitor CUDC-907 as a novel senolytic
por: Al-Mansour, Fares, et al.
Publicado: (2023)

Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG)
por: Kuin, A, et al.
Publicado: (1999)

A convenient Simple Method for Synthesis of Meta-iodobenzylguanidine (MIBG)
por: Sheikholislam, Zahra, et al.
Publicado: (2013)

Analysis of quantitative [I-123] mIBG SPECT/CT in a phantom and in patients with neuroblastoma
por: Brady, Samuel L., et al.
Publicado: (2019)

Reproducibility of planar (123)I-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy in patients with heart failure
por: Veltman, Caroline E., et al.
Publicado: (2012)

EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for (131)I mIBG treatment of neuroendocrine tumours
por: Gear, Jonathan, et al.
Publicado: (2020)

Dual Targeting of PI3K and HDAC by CUDC-907 Inhibits Pediatric Neuroblastoma Growth
por: Chilamakuri, Rameswari, et al.
Publicado: (2022)

Misdiagnosis of Paraganglioma by (123)I-mIBG Without Stable Iodine Blockade of Thyroidal Radioiodine Uptake
por: Chen Cardenas, Stanley M, et al.
Publicado: (2020)

Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides
por: Millul, Jacopo, et al.
Publicado: (2023)

Comparison Between Diffusion‐Weighted MRI and (123)I‐mIBG Uptake in Primary High‐Risk Neuroblastoma
por: Privitera, Laura, et al.
Publicado: (2020)

Can early phase cardiac [(123)I]mIBG images be used to diagnose Lewy body disease?
por: Roberts, Gemma, et al.
Publicado: (2022)

Therapeutic Potential of CUDC-907 (Fimepinostat) for Hepatocarcinoma Treatment Revealed by Tumor Spheroids-Based Drug Screening
por: Liao, Wei, et al.
Publicado: (2021)

Improved outcome of (131)I-mIBG treatment through combination with external beam radiotherapy in the SK-N-SH mouse model of neuroblastoma
por: Corroyer-Dulmont, Aurélien, et al.
Publicado: (2017)

(123)I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting ,method by an international panel
por: Lewington, V., et al.
Publicado: (2016)

The relation between cardiac (123)I-mIBG scintigraphy and functional response 1 year after CRT implantation
por: Verschure, D O, et al.
Publicado: (2020)

The prognostic value of (123)I-mIBG SPECT cardiac imaging in heart failure patients: a systematic review
por: Pontico, Mariano, et al.
Publicado: (2021)

Comparison of Taiwanese and European Calibration Factors for Heart-to-Mediastinum Ratio in Multicenter (123)I-mIBG Phantom Studies
por: Okuda, Koichi, et al.
Publicado: (2023)

Role of cardiac (123)I-mIBG imaging in predicting arrhythmic events in stable chronic heart failure patients with an ICD
por: De Vincentis, Giuseppe, et al.
Publicado: (2018)

The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML
por: Qiao, Xinan, et al.
Publicado: (2021)

Impact of Diabetes on Cardiac Sympathetic Innervation in Patients With Heart Failure: A (123)I meta-iodobenzylguanidine ((123)I MIBG) scintigraphic study
por: Paolillo, Stefania, et al.
Publicado: (2013)

Thrombocytopenia after meta-iodobenzylguanidine (MIBG) therapy in neuroblastoma patients may be caused by selective MIBG uptake via the serotonin transporter located on megakaryocytes
por: Blom, Thomas, et al.
Publicado: (2021)

Cardiac sympathetic activity in chronic heart failure: cardiac (123)I-mIBG scintigraphy to improve patient selection for ICD implantation
por: Verschure, D. O., et al.
Publicado: (2016)

Pluripotent stem cell‐based screening identifies CUDC‐907 as an effective compound for restoring the in vitro phenotype of Nakajo‐Nishimura syndrome
por: Kase, Naoya, et al.
Publicado: (2020)

CUDC907, a dual phosphoinositide-3 kinase/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells
por: Huegel, Julianne, et al.
Publicado: (2022)

Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications
por: Gaonkar, Raghuvir Haridas, et al.
Publicado: (2023)

OR03-01 Effects Of Alpha-emitting Meta-(211)At-astato-benzylguanidine ((211)At-MABG) Compared To (131)I-meta-iodobenzylguanidine ((131)I-MIBG) on Tumor Growth Suppression in a Pheochromocytoma Mouse Model
por: Yoshinaga, Keiichiro, et al.
Publicado: (2020)

Objective comparison of lesion detectability in low and medium-energy collimator iodine-123 mIBG images using a channelized Hotelling observer
por: Gregory, Rebecca A, et al.
Publicado: (2017)

Myocardial (123)I-mIBG scintigraphy in relation to markers of inflammation and long-term clinical outcome in patients with stable chronic heart failure
por: Verschure, Derk O., et al.
Publicado: (2016)

CUDC‐907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action
por: Hu, Cheng, et al.
Publicado: (2020)

Dual inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 attenuates TGFβ1 induced lung and tumor fibrosis
por: Zhang, Wentian, et al.
Publicado: (2020)

Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia
por: Li, Xinyu, et al.
Publicado: (2019)

Correction to: Pluripotent Stem Cell-Based Screening Identifies CUDC-907 as an Effective Compound for Restoring the In Vitro Phenotype of Nakajo-Nishimura Syndrome
Publicado: (2022)

131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.
por: Gaze, M. N., et al.
Publicado: (1992)

Cannot write session to /tmp/vufind_sessions/sess_0a7ku7ldf3jbc70230ubcaena1